Добірка наукової літератури з теми "Virus Oncolitici"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Virus Oncolitici".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Virus Oncolitici"
Klaan, N. K., L. P. Аkin’shina, and T. A. Pronina. "Oncolitical viruses in the therapy of malignant neoplastic diseases." Russian Journal of Biotherapy 17, no. 4 (January 11, 2019): 6–19. http://dx.doi.org/10.17650/1726-9784-2018-17-4-6-19.
Повний текст джерелаManso, L., P. Villagrasa, N. Chic, J. M. Cejalvo, Y. Izarzugaza, B. Cantos, S. Blanch, et al. "41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)." Annals of Oncology 31 (May 2020): S30. http://dx.doi.org/10.1016/j.annonc.2020.03.175.
Повний текст джерелаДисертації з теми "Virus Oncolitici"
Petrovic, Biljana <1987>. "Nuove strategie di reindirizzamento nel disegno di virus Herpes Simplex oncolitici." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2017. http://amsdottorato.unibo.it/7979/1/Petrovic_Biljana_tesi.pdf.
Повний текст джерелаOncolytic virotherapy exploits the ability of viruses to infect and kill cells and is envisioned as treatment for tumors that respond poorly to the current therapeutic approaches. The attenuated herpes simplex virus 1 (HSV-1), named T-Vec, is the only oncolytic virus approved so far for clinical practice. Safety was obtained at the expense of virulence. To overcome the attenuation limits, an alternative strategy consists in altering the host range of a virus. The binding of membrane-bound glycoprotein D (gD) of HSV-1 to one of its receptors activates the downstream glycoproteins gH/gL and gB. The latter executes the fusion virion-cell. So far, gD was the only glycoprotein that successfully enabled the retargeting of HSV-1. The work of this thesis focuses on the the development of oncolytic herpes simplex viruses (o-HSVs), retargeted to tumor-specific receptors, in order to bring retargeted o-HSVs to the translational phase. The tropism of HSV-1 has been modified by engineering a heterologous ligand in gH (in virus R-809) or in gB (in R-909). The selected heterologous ligand was a single chain variable fragment antibody (scFv) directed against HER2, a receptor overexpressed in several cancers. The retargeting achieved via gB or gH confers to HSV-1 very similar properties to the retargeting achieved via gD, in terms of virus growth and oncolytic activity in vitro. The changes in gB or gH were combined with those in gD, leading, for the first time, to two HSV-1 simultaneously redirected to two distinct receptors. R-805, directed simultaneously to HER2 and EGFR, has been characterized in vitro. An in vivo model to study its oncolytic efficacy was developed. R-313 was designed to enable the production of an oncolytic vector into a non-tumor cell line. R-313 is capable to use alternately two receptors, and to infect the tumor cells and the non-tumor-producing cells.
REALE, ALBERTO. "Ottimizzazione preclinica di vettori oncolitici basati sul virus herpes simplex di tipo 1." Doctoral thesis, Università degli studi di Padova, 2022. http://hdl.handle.net/11577/3448137.
Повний текст джерелаOncolytic viruses (OVs) are emerging therapeutics that selectively replicate in cancer cells, either naturally or following genetic engineering. OVs also elicit an immune response against cancer and are therefore an immunotherapeutic tool. Furthermore, OVs can be modified to express therapeutic genes. An OV based on an attenuated herpes simplex virus type 1 (HSV-1), talimogene laherparepvec (T-VEC), has been approved in the US in 2015 and in the EU in 2016 for the treatment of advanced-stage malignant melanoma. T-VEC has deletions in the neurovirulence γ34.5 gene and Us12 gene (Δγ34.5/ΔUs12) and is further armed with human granulocyte-monocyte colony stimulating factor (hGM-CSF) gene. Our research group developed several oncolytic HSV-1 (oHSV1s) with a Δγ34.5/ΔUs12 backbone, armed with an array of immunotherapeutic genes other than GM-CSF. During this PhD project, we focused on developing a systemic delivery system by means of carrier cells, to achieve a pre-clinical optimization of oncolytic HSV-1. Monocytes were chosen because 1)they have an inherent tropism for tumors, being the precursors of tumor associated macrophages (TAMs), 2)they are capable of migrating into most compartments of the body, including the central nervous system, 3)autologous monocytes can be easily recovered in large amount from peripheral blood. Using the human monocytic cell line THP-1, we demonstrated that monocytic cells can migrate towards human breast cancer cells and transmit oHSV1 infection. These findings were confirmed with primary human monocytes. THP-1 cells also delivered oHSV1 to human head-and-neck UM-SC-11B cancer cells growing on the chorioallantoic membrane (CAM) of embryonated chicken eggs, following intravascular injection. Finally, we developed a new miRNA-based neuroattenuation system for oHSV1 to enhance safety following intravenous injection.
RINALDI, Francesca. "Strategie di Costruzione di Vettori Erpetici Oncolitici per la Cura del Tumore Epatico." Doctoral thesis, Università degli studi di Ferrara, 2009. http://hdl.handle.net/11392/2389149.
Повний текст джерелаSgubin, Donatella. "Cellule Staminali di Glioblastoma: Terapia Oncolitica con Vettori Erpetici Ingegnerizzati." Doctoral thesis, Università degli studi di Trieste, 2014. http://hdl.handle.net/10077/10157.
Повний текст джерелаIl Glioblastoma (GBM), nonostante i migliori standard terapeutici, rimane una patologia a prognosi infausta. L’ipotesi delle Glioma Stem-like Cells (GSCs) prevede che, nella massa tumorale, sia presente una popolazione di cellule resistenti alla chemio e radioterapia e che tali cellule siano quindi le possibili responsabili della recidiva di malattia. Le GSCs, che possiedono caratteristiche comuni alle cellule staminali fisiologicamente presenti nel cervello adulto, sono cellule a lenta crescita, capaci di self-renewal, esprimono marker di staminalità, sono multipotenti e sono tumorigeniche quando vengono impiantate in vivo in modelli murini, formando lesioni istologicamente identiche a quelle originarie. Il relativo fallimento delle terapie ad oggi in uso ha portato a studiare nuove strategie dirette verso le GSCs e non soltanto verso le cellule a rapida divisione. Le terapie con virus oncolitici rappresentano, in questi termini, un approccio promettente. L’Herpes Simplex Virus di tipo 1 (HSV-1) è uno dei vettori più studiati e, nelle sue forme mutate, risulta sicuro ed efficace in vitro e in vivo. Questo studio dimostra come G47!, forma multimutata dell’HSV-1, sia in grado di infettare, replicarsi e uccidere le GSCs derivanti da linee primarie di GBM in vitro e in vivo sia in normossia, che in ipossia, condizione che, oltre ad essere comune in questo tumore, arricchisce la popolazione cellulare con caratteristiche stem-like. In questo progetto si descrive inoltre una nuova forma mutata di G47! denominata G47!Us11fluc, in cui il virus esprime luciferasi come gene late del ciclo di replicazione virale, offrendo una stima precisa del virus yield, nonchè un metodo di visualizzazione in tempo reale, con sistemi a bioluminescenza, della replicazione virale in vivo.
XXVI Ciclo
1980